Lowering LDL Cholesterol in Adults: A Prospective, Community-Based Practice Initiative

American Journal of Medicine

Volumn 121, Issue 7, 2008, Pages 604-610

  Coodley, Gregg O ^a   Jorgensen, Maryclair ^a   Kirschenbaum, Jack ^a   Sparks, Chieko ^a   Zeigler, Lisa ^a   Albertson, Barry D ^a  

^a Fanno Creek Clinic   (United States)

Author keywords

Adults; Community based internal medicine clinic; Low density lipoprotein cholesterol (LDL)

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMMUNITY CARE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; EXERCISE; FEMALE; FOLLOW UP; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DIET; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INTERVENTION STUDIES; LIFE STYLE; MALE; MIDDLE AGED; OREGON; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 45849125737     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.02.031     Document Type: Article

References (42)

1. Summary of the second report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
4. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19 (1998) 1434-1503
5. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high risk patient. In: Scott M. Grundy, MD, PhD, Guest Editor. Managing cardio-metabolic risk: will new approaches improve success? Am J Med (Suppl).r 2007;120(9A):S3-S9.
6. Statins for high-risk patients without heart disease or high cholesterol. Med Lett Drugs Ther 48 1225 (2006) 1-3
7. Crouse J., Elam M., Robinson J., et al. Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. Am J Cardiol 97 11 (2006) 1667-1669
8. Kastelei J.J.P., and Sankatsing R.R. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidemia. Int J Clin Pract 59 12 (2006) 1464-1467
9. Kermani T., and Frishman W. Non-pharmacologic approaches for the treatment of hyperlipidemia. Cardiol Rev 13 5 (2005) 247-255
10. McKenney J. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 96 4A (2005) 60E-66E
11. Grundy S.M. Stano6l esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult treatment Panel III report. Am J Cardiol 96 1A (2005) 47D-50D
12. Simons L.A., and Sullivan D.R. Lipid-modifying drugs. Med J Aust 182 6 (2005) 286-289
13. Stein E.A. Managing dyslipidema in the high-risk patient. Am J Cardiol 98 5A (2002) 50C-57C
14. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein goals. Arch Intern Med 160 (2000) 459-467
15. Kannel W.B., and Larson M. Long-term epidemiologic prediction of coronary disease: the Framingham experience. Cardiology 82 2-3 (1994) 137-152
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
17. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995) 1301-1307
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
19. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
20. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
21. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events, with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
22. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent CNCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
23. Fonarow G.C., and Gawlinski A. Rationale of design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol 85 (2000) 10A-17A
24. Birtcher K.K., Bowden C., Ballantyne C.M., and Huyen M. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol 85 (2000) 30A-35A
25. Fonarow G.C., Gawlinski A., Moughrabi S., and Tillisch J.H. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
26. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
27. Faul F., Erdfelder E., Lang A.-G., and Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39 2 (2007) 175-191
28. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 343-344
29. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149 (1989) 1514-1520
30. Nicholls S.J., Mural Tuzcu E., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary athrosclerosis. JAMA 297 5 (2006) 499-508
31. Genest J.J., McNamara J.R., Ordovas J.M., et al. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol 19 (1992) 792-802
32. Deedwania P.C., Hunninghake D.B., and Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol 93 11A (2004) 18C-26C
33. Davidson M.H. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol 93 11A (2004) 3C-11C
34. Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 13 (2004) 1427-1436
35. LaRosa J.C., Grundy S.M., Waters D.D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
36. Ellrodt G., Cook D.J., Lee J., Cho M., Hunt D., and Weingarten S. Evidence-based disease management. JAMA 278 20 (1997) 1687-1692
37. Hunter D.J., and Fairfield G. Disease management. BMJ 315 (1997) 50-52
38. Weingarten S.R., Henning J.M., Badamgarav E., et al. Interventions used in disease management programmes for patients with chronic illness-which ones work?. Meta-analysis of published reports. BMJ 325 (2002) 925-928
39. Knight K., Badamgarav E., Henning J.M., et al. A systematic review of diabetes disease management programs. Am J Manag Care 11 (2005) 242-250
40. Krause D.S. Economic effectiveness of disease management programs: a meta-analysis. Dis Manage 8 (2005) 114-134
41. Ofman J.J., Badamgarava E., Henning J.M., et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases?. A systematic review. Am J Med 117 (2004) 182-192
42. Grover S.A., Lowensteyn I., Joseph L., et al. Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP Study: a randomized controlled trial. Arch Intern Med 167 21 (2007) 2296-2303